CISION PRNewswire

61522 posts
Farmmi Ships High-Volume Repeat Order to Chile; Company Sees Golden Age for Mushrooms

Farmmi Ships High-Volume Repeat Order to Chile; Company Sees Golden Age for Mushrooms

LISHUI, China, Nov. 27, 2023 /PRNewswire/ — Farmmi, Inc. ("Farmmi" or the…
Inter(World)View, Interview the World

Inter(World)View, Interview the World

HANGZHOU, China, Nov. 27, 2023 /PRNewswire/ — This November, as the core…
AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer – published in npj Precision Oncology

AI-Powered TIL Analysis by Lunit Unveils Prognostic Insights for Colon Cancer – published in npj Precision Oncology

AI-powered spatial analysis of tumor-infiltrating lymphocytes using Lunit SCOPE IO provides accurate prognosis…
Moomoo's Cash Sweep Program Offers A Highly Competitive 5.1% APY; Increases Cash Management Efficiency

Moomoo's Cash Sweep Program Offers A Highly Competitive 5.1% APY; Increases Cash Management Efficiency

PALO ALTO, Calif., Nov. 27, 2023 /PRNewswire/ — The intuitive investment and trading…
Hikvision and Logistics Management Magazine unveil new white paper on AI-driven innovations in logistics

Hikvision and Logistics Management Magazine unveil new white paper on AI-driven innovations in logistics

HANGZHOU, China, Nov. 27, 2023 /PRNewswire/ — As a response to the…
AWAK Technologies Announces FDA Breakthrough Device Designation for their Artificial Intelligence Enabled Kidney Disease Prediction Tool

AWAK Technologies Announces FDA Breakthrough Device Designation for their Artificial Intelligence Enabled Kidney Disease Prediction Tool

SINGAPORE, Nov. 27, 2023 /PRNewswire/ — AWAK Technologies (AWAK), a pioneering medical…
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients

HONG KONG, Nov. 27, 2023 /PRNewswire/ — Akeso (9926. HK) has announced that…